UNSPSC 85632347: Supplement right breast with autologous tissue substitute, via natural or artificial opening endoscopic

This classification denotes the group of activities that yields a surgical intervention or procedure to supplement right breast with autologous tissue substitute, via natural or artificial opening endoscopic. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 0HUT87Z

UNSPSC 85632347 (Supplement right breast with autologous tissue substitute, via natural or artificial opening endoscopic), a Commodity code, shows minimal alignment with actual state and local procurement activity. Recent opportunities tagged under this code do not involve breast augmentation procedures or surgical implantation; instead, they span occupational medical surveillance, pharmacy benefit management, disability benefit medical evaluations, temporary health professional staffing, and surgical benefit program administration—none of which match the code's clinical procedure scope. The mismatch suggests either miscategorization at the source level or a fundamental disconnect between how this code is intended and how it is being applied in state and local contracting.

The recent opportunities that have been tagged under this code originate from diverse issuing bodies including state departments (Washington State Department of Transportation), counties (Harris County, Collier County, Santa Clara County), cities (Phoenix, Long Beach), and health systems. The geographic spread spans Washington, Arizona, California, Florida, and Texas, with no clear concentration. Representative recent solicitations include the Washington State Department of Transportation's RFP for occupational medical surveillance services (due October 9, 2026), the City of Phoenix Retirement Office's RFP for independent medical evaluation services (due October 16, 2026), and the City of Long Beach's RFP for a surgical and medical procedure carve-out benefit program (due October 7, 2026). Given the consistent absence of breast reconstruction or tissue-graft procurement across these records, firms pursuing opportunities under this code should verify the actual clinical or administrative service required in each solicitation rather than relying on the code's nominal description.